Background Poor treatment results obtained with palliative chemotherapy for advanced gastric cancer indicate the need for new effective and well-tolerated regimens
Introduction
In Western countries, the incidence of gastric cancer approximates 30-35 cases per 100.000 per year, with a tendency to decrease. Nevertheless, this tumour is among the five most frequent malignancies and the seventh most frequent cause of death from cancer. The treatment of choice for localized (stage I-II la) disease is potentially curative resection consisting of either subtotal or total gastrectomy or radical surgery. Regional lymphadenectomy is recommended with all of the above procedures. The five-year survival rates after R0 resection are approximately 70%-80% in stage I, 50%-60% in stage II, 20%-30% in stage III, and less than 5% in stage IV [1] . Cure is no longer possible in patients with advanced (stage IIIb-IV) disease, with a median survival of 6 to 9 months [2] . Thus, for the majority of patients with recurrent or metastatic gastric cancer palliative chemotherapy is the only reasonable therapeutic option.
Single agent chemotherapy with doxorubicin, cisplatin, 5-fluorouracil (5-FU), or mitomycin C which have long been considered the most active drugs in this setting, produced response rates in the range of 20%-30% [3] . Dual and triple combinations often produced higher response rates in the range of 30% to more than 50%, with prolonged duration of responses (6-9 months) but median overall survival usually did not exceed one year in phase II trials or six to seven months in randomized trials [4] . As survival is poor with all available treatment regimens, patients with advanced gastric cancer should be included in clinical trials of new agents or combinations Docetaxel is a novel semisynthetic taxoid which has demonstrated activity against human gastric carcinoma cell lines in vitro and in vivo [5] , Using this agent for the treatment of patients with advanced or metastatic gastric cancer resulted in a response rate of 22%-24% when given as first-line therapy [6, 7] and 18%-24% as secondline therapy [8, 9] . Recently, two studies reported high response rates of 45% [10] and 53% [11] with the combination of docetaxel and cisplatin. The present study was performed to confirm these results and evaluate the tolerability of docetaxel-cisplatin given at moderate doses to patients with locally advanced or metastatic gastric cancer. Dosage and administration intervals chosen are based on results of a previous study, which aimed to elucidate optimal regimen combining both drugs. A dosage higher than 80 mg/m 2 of docetaxel-cisplatin was too toxic.
Patients and methods

Patient selection
Patients aged between 18 and 75 years with histologically confirmed locally advanced inoperable (T 3^, N X M O ) or metastatic (T,N,M,) cancer of the stomach were considered for enrollment in the study Other eligibility criteria included bidimensionally measurable disease using computed tomography, life expectancy of more than three months. World Health Organization (WHO) performance status <2, normal organ function (laboratory parameters within normal institutional limits), and no chemotherapy within four weeks prior to enrollment All study candidates were required to provide written informed consent before initiation of the study Patients with one or more of the following conditions were ineligible for the study second malignancy, previous palliative chemotherapy with docetaxel or cisplatin except adjuvant treatment for more than six months, clinical evidence of metastases to the central nervous system, peripheral neuropathy WHO grade ?2, history of significant concomitant medical disease, or pregnancy Prior to enrollment, all patients underwent a thorough clinical assessment including medical history, physical examination and imaging studies (computed tomography of thorax and abdomen, abdominal ultrasound, chest X-ray in two planes) Relevant laboratory parameters including tumour markers (CEA, CA 72/4, and CA 19/9) were assessed before study entry and on a regular basis during and after treatment Tumours were diagnosed and staged according to theTNM classification using computed tomography, gastroscopy (including biopsy), ultrasound-guided biopsy by puncture of a tumour metastasis in case of melastatic disease, or exploratory laparotomy Tumour stage was reclassified after three cycles of chemotherapy Standard WHO criteria for response and toxicity were used All patients who received more than three cycles of chemotherapy were evaluable for response and time to progression Patients who received at least one cycle of chemotherapy were evaluable for toxicity, and all patients were included in the survival analysis Chemotherapy consisted of docetaxel (Taxotere®, Rhone-Poulenc Rorer Arzneimittel GmbH, Cologne, Germany) 75 mg/m 2 and cisplatin 75 mg/m 2 Both drugs were administered by intravenous infusion over one hour on day 1 Treatment was repeated every three weeks for six cycles In case of minimal or partial response, three further cycles were administered (maximum, nine cycles) The doses of both docetaxel and cisplatin were reduced by 20%, i e , to 60 mg/m 2 if the leukocyte count fell to s^OOO/mnv 1 or if other toxicities WHO grade >3 occurred Anti-emetic prophylaxis using ondansetron was given routinely In addition, all patients received intravenous dexamethasone (16 mg on day -1, 8 mg on day 0, and 16 mg on day 1) to prevent docetaxelinduced hypersensitivity reactions Cisplatin was given with hyperhydration (1000 ml Ringer's lactate solution) and mannitol diuresis If an acute hypersensitivity reaction, as characterized by dyspnea, bronchospasm, hypertension, or pruritus, developed in a patient during infusion of docetaxel, the infusion was interrupted and antihistaminic medication given The drug infusion was continued after disappearance of the allergic symptoms If leukocyte counts fell below 2000/mm 3 , G-CSF (Granocyte 34 W , Rhone-Poulenc Rorer Arzneimittel GmbH, Cologne. Germany) was administered subcutaneously until recovery of the white blood count Patients were withdrawn from further protocol treatment if their tumour failed to respond or if tumour progression or unacceptable loxicity occurred
The first objective of this phase II trial was to determine i) the response rate of docetaxel and cisplatin in patients with advanced gastric carcinoma and n) toxicity rate of this regimen Using an onesided test for differences, efficacy was calculated with two steps in 35 patients planned for enrollment (a, 5%, p\ 20%) The '0' hypothesis was that there is an ineffective chemotherapy protocol if the response rate is ^ 20%. and it is considered effective if the rate is > 40%
The data are presented using descriptive statistics Survival was estimated by the product limit method of Kaplan and Meier and calculated from the date of enrollment to time of death or last followup 
Results
Patient characteristics
From January 1997 to October 1998, 43 patients (30 men, 13 women) with locally advanced (n -8) or metastatic (n -35) gastric cancer were enrolled in the study. Baseline characteristics are shown in Table 1 . Nineteen patients had primary advanced disease, and twenty-four had recurrent disease. Relapse had occurred a median of 36 months after primary treatment. Fifteen patients had an intestinal type of gastric cancer, and twenty-five patients had a diffuse type according to the classification of Lauren. Ten patients had undergone curative and seven patients palliative gastrectomy, two patients had a 4/5 curative resection, two a curative Billroth II resection and three patients a palliative gastroenterostomy. Nineteen patients were inoperable at the time of diagnosis Six patients had received adjuvant chemotherapy with cisplatin, 5-FU and folinic acid more than twelve months 43 6) prior to entry into the study. The response to treatment could not be evaluated in four patients. Two of these patients withdrew their consent and chemotherapy was discontinued prior to the first restaging of the tumour. Two other patients died of progressive disease after the first cycle of chemotherapy. Systemic side effects of these two patients after the first cycle of chemotherapy were also evaluated resulting in a total number of 43 patients in whom toxicity rate could be determined
Drug exposure
A total of 267 chemotherapy cycles were administered (mean 6.2 cycles per patient, median 6, range 1-12). The individual delivered dose of both docetaxel and cisplatin ranged from 75 to 900 mg/m 2 . Treatment was extended to twelve cycles in a patient with a partial response who expressed the wish for further therapy. The dose was reduced once or more in 12 patients (28%) and in 23 cycles (10%). In one patient treatment had to be discontinued due to WHO grade 4 haematological toxicity.
Efficacy
The efficacy data are shown in Table 2 . Four of the thirty-nine evaluable patients achieved a complete response (CR) and twelve a partial response (PR) For the intent-to-treat analysis, an overall response rate of 37.2% (95% CI: 22.98-53.72). In addition, 1 patient had a minor response, and 10 patients (26%) had stable disease that persisted for a median of 4.5 months. Twelve patients had an progressive disease and it was an treatment failure for this patients. The CRs occurred after three cycles of chemotherapy. Three of the four complete responders had primary stage IV disease (multiple liver metastases in two patients and lymph node metastases in one patient), while one patient had stage III disease. Three patients who achieved a CR with docetaxel and cisplatin subsequently underwent surgery (two had R0 resection and one Rl resection). The median duration of CR could not be determined since three of four patients underwent resection.
The median time to tumour progression was 6.1 months (range 2.3-9 months), and median overall survival was 10.4 months. Eighteen (42%) of the forty-three 
Safely
Toxicity was evaluable in all 43 patients and 228 chemotherapy cycles The toxicity data after six and more than six cycles are presented in Tables 3 and 4 . In case of minimal or partial response, three further cycles were administered (maximum nine cycles) The most frequent haematological toxicity was leukopenia (WHO grade 3 or 4 in 18.6% of the patients). The leukocyte nadir was reached seven days after the administration of chemotherapy. Eight patients (18.6%, n = 43) with leucopenia >3 according to classification by WHO received G-CSF daily until leucocyte count reached normal range. Neutropenic fever was not observed during the study, and fever and infections occurred infrequently and did not exceed grade 2. Gastrointestinal side effects included nausea and vomiting (7% grade 3) and diarrhea (9% grade 3) Alopecia was usually mild to moderate (grade 3 in 7% of the patients) No signs of fluid retention and nephrotoxicity were noted. Skin reactions were moderate. They appeared as redness with partly accompanying itch as sign of hypersensitive response. Follow-up assessments conducted after conclusion of the study revealed an increase in ototoxicity with or without peripheral neuropathy in two patients. One patient developed symptomatic hearing loss and severe sensory neuropathy with hyperaesthesia of the fingers after nine cycles of treatment. Hearing loss improved after six months while paraesthesias persisted. In the other patient irreversible severe hearing loss occurred after 12 cycles. In these patients the therapy was given over 12 cycles on patient's request in contradiction to the protocol.
Discussion
Patients with recurrent or metastatic gastric cancer can benefit from palliative chemotherapy. Some controlled trials of combination chemotherapy have revealed a significant improvement in median survival and quality of life compared with best supportive care alone [12, 13] but at present there is no generally accepted standard regimen Most of the more commonly used regimens contain 5-FU and/or cisplatin, often in combination with an anthracycline, methotrexate, etoposide or mitomycin C. However, no substantial progress has been achieved in the chemotherapy of advanced gastric cancer during the past decade, and many patients, particularly those with poor performance status or compromised organ function cannot tolerate the toxic treatment. This has recently prompted investigators to include promising new drugs such as the taxanes into combination regimens to increase efficacy and hopefully decrease toxicity.
Our trial demonstrated that the combination of docetaxel and cisplatin is an active and well tolerated regimen. The overall response rate of 41% indicates an increase in antitumour activity compared with single agent docetaxel in patients with no previous chemotherapy for advanced disease [6] . Moreover, activity appears comparable with common two-or three-drug combinations including FAMTX (5-FU, doxorubicin, methotrexate) [14] , ELF (etoposide, leukovorin, 5-FU) [15, 16] or FAP (5-FU, doxorubicin, cisplatin) [17] . Four (10%) of thirty-nine evaluable patients in our study achieved a long-lasting complete response after three courses of chemotherapy. All but one of these patients had primary metastatic disease including multiple liver or lymph node metastases. One patient with locally advanced disease showed a complete regression of his lesions. Surgery could be performed in three of the complete responders, indicating a potentially usefulness of this regimen as neoadjuvant therapy.
In their phase I-II study, Roth et al. used a similar docetaxel-cisplatin regimen with the same dose of cisplatin (75 mg/m 2 ) but a higher dose of docetaxel (85 mg/m 2 ) every three weeks. They reported a response rate of 53% (2 CRs and 22 PRs) among 45 evaluable patients [11] An attempt to further increase the docetaxel dose to 100 mg/m 2 was abandoned because of unacceptable toxicity. Median time to progression and overall survival were 7.0 and 8.6 months, respectively, in that study compared with 6.1 and 10.4 months in the present study So despite a slightly lower response rate the median overall survival in our study was at least equivalent, with an encouraging one-year survival rate of 42%. A group from Greece [10] used a three-weekly high-dose regimen of docetaxel 100 mg/m 2 on day 1 and cisplatin 80 mg/m 2 on day 2 with G-CSF support They reported a response rate of 45%, a median time to progression of 8.3 months and median survival of 11 months, with a one-year survival of 48% Thus, their treatment results do not suggest a clear advantage compared with the lower doses used in our study. Treatment could be administered at the planned doses in 90% of the cycles in our study. The predominant toxicity was severe leukopenia in 18.6% of the patients (n -8), and grade 4 leukopenia was the reason for discontinuation of treatment in one patient Non-haematological toxicity was mild to moderate in the majority of patients and consisted mainly of nausea /vomiting, diarrhea and alopecia. No severe hypersensitivity reactions or any clinical signs of fluid retention were detected. This may be due to the corticosteroid prophylaxis given routinely with each dose of docetaxel.
Thus, the use of docetaxel at a moderate dose of 75 mg/m 2 in combination with cisplatin appears to result in much less haematological toxicity compared with higher doses. Although patient characteristics were similar to those in our study, Roth et al. [11] reported grade 3 or 4 neutropenia in 68% of the patients, includ-ing nine episodes of febrile neutropenia, as well as mild to moderate fluid retention in 32% of the patients. Alopecia was also more pronounced (grade 3-4 in 36%). In the Greek study [10] 43% of 53 patients developed grade 3-4 neutropenia despite the use of G-CSF. Fifteen patients were hospitalized for neutropenic fever, and two patients died of sepsis.
Nevertheless, we were concerned about two cases of late severe ototoxicity occurring in our study. One of these patients also suffered from irreversible hyperaesthesias of the fingers. Hearing loss worsened in these patients to grade 4 after completion of chemotherapy (6 and 12 courses, respectively) and did not improve in the later course of the disease in one of them. Ototoxicity is a well recognized and frequent side effect of cisplatin that is related to both cumulative dose and dose-density of the drug [18] . Carboplatin, another platinum derivative, is considerably less ototoxic than cisplatin and relatively free from neurotoxicity [19] Carboplatin has also shown activity in gastric cancer in vivo [20] and in a clinical study [21] . Thus, it seems worthwhile to combine docetaxel with carboplatin to further improve the tolerability of chemotherapy in the palliative setting.
In conclusion, the combination of docetaxel and cisplatin is an active and relatively well tolerated regimen at the doses used in our study, with moderate and manageable myelotoxicity. Non-heamatological toxicity including nausea/vomiting and alopecia was rarely severe. Considering the results obtained in other studies of docetaxel and cisplatin, the use of these agents at higher doses does not appear to improve antineoplastic activity but increase toxicity considerably
